Compositions and methods for gene editing
Fusion proteins with DNA methyltransferase and nuclease-deficient RNA-guided endonucleases provide a safer and more controlled method for gene silencing, addressing genotoxicity risks and achieving durable, specific gene expression regulation.
Patent Information
- Application Number
- AU2026203640
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-05-12
- Publication Date
- 2026-07-23
AI Technical Summary
Genome editing technologies face risks of genotoxicity from double strand breaks and an all-or-none effect on target genes, while targeted epigenome engineering offers a safer and more graded control of gene expression.
Fusion proteins comprising a DNA methyltransferase domain, XTEN linkers, and a nuclease-deficient RNA-guided endonuclease enzyme, such as CRISPR-associated proteins, are used to silence target nucleic acid sequences, allowing for controlled gene expression without the risks of genotoxicity.
The fusion proteins achieve durable, multiplexed, and highly specific silencing of target genes, reducing genotoxicity and enabling graded control of gene expression, as demonstrated by prolonged silencing and reduced viral infection rates.
Smart Images
Figure 00000167_0000 
Figure 00000167_0001 
Figure 00000167_0002